eligibility_summary
Adults ≥18 with relapsed/refractory CD19/20+ B‑cell NHL (exclude primary CNS, CLL/Burkitt), ≥2 prior chemo and anti‑CD20, measurable disease, ≥5% CD19/20, ECOG 0–1, survival >16 wks, consent/compliance, contraception. Exclude: CNS disease, major autoimmune, transplant with immunosuppression/GvHD, anti‑CD20 <2 wks, organ dysfunction, CV disease, chronic steroids, key drug allergies (sulfa, albumin, DMSO), TB+, uncontrolled HIV, HBsAg+, other cancer, pregnant/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06334991 tests: 1) CD19 t-haNK: a biological, off‑the‑shelf, allogeneic NK‑92–derived CAR‑NK cell therapy. It expresses an anti‑CD19 CAR for direct recognition/killing of CD19+ B cells, secretes endoplasmic reticulum–retained IL‑2 to support NK activation/persistence, and incorporates the high‑affinity CD16a (FcγRIIIa V158) to enhance antibody‑dependent cellular cytotoxicity (ADCC). 2) Rituximab: a chimeric IgG1 monoclonal antibody against CD20 that mediates B‑cell killing via ADCC, complement‑dependent cytotoxicity (CDC), and apoptosis. Targets/pathways: CD19 and CD20 on malignant B cells, NK cell effector mechanisms including CAR signaling, perforin/granzyme cytotoxicity, IL‑2–driven activation, and FcγRIIIa‑mediated ADCC (synergizing with rituximab), plus complement activation via rituximab.